Fam-trastuzumab deruxtecan

德曲妥珠单抗

Report date: 2026/05/12 20:00:17

Base Information

Drug NameFam-trastuzumab deruxtecan
Drug Alias Namefam-trastuzumab deruxtecan-nxkitrastuzumab deruxtecanEnhertu优赫得優赫得 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payload > MAAA-1181a payload
Mechanisms of ActionDNA topoisomerase I inhibitorsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerGastroesophageal Junction Neoplasms +[25] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryUnited States
Original Approved Date2019/12/20
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[48] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo (China) Holdings Co LtdIqvia Rds (Shanghai) Co LtdThe Netherlands Cancer Institute +[17] 
Inactive CompaniesShanghai Jiao Tong University School of MedicineNational Cancer InstituteSun Yat-Sen University
Active IndicationsBrain metastasesMetastatic breast cancerGastroesophageal Junction Neoplasms +[22] 
Inactive IndicationsGastrointestinal NeoplasmsOsteosarcomaNeoplasms

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG